Hoeger Bement M, St Marie B, Nordstrom T, Christensen N, Mongoven J, Koebner I, Fishman S, Sluka K. An Interprofessional consensus of core competencies for prelicensure education in pain management: curriculum application for physical therapy. Phys Ther. 2014;94:451–64.

Article  Google Scholar 

Bouhassira D, Lantéri-Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain. 2008;136:380–7.

Article  Google Scholar 

Attal N, Lanteri-Minet M, Laurent B, Fermanian J, Bouhassira B. The specific disease burden of neuropathic pain: results of a French nationwide survey. Pain. 2011;152:2836–43.

Article  Google Scholar 

Buchbinder R, Tulder M von, Öberg B, Menezes Costa L, Woolf A, Schoene M, Croft P, Lancet Low Back Pain Series WG. Low back pain: a call for action. Lancet. 2018;391: 2384–2388.

Behrman M, Linder R, Assadi AH, Stacey BR, Backonja M-M. Classification of patients with pain based on neuropathic pain symptoms: comparison of an artificial neural network against an established scoring system. Eur J Pain. 2007;11:370–6.

Article  Google Scholar 

Mathieson S, Maher CG, McLachlan AJ, Latimer J, Koes BW, Hancock MJ, Harris I, Day RO, Billot L, Pik K, Jan S, Lin C-WC. Trial of pregabalin for acute and chronic sciatica. N Engl J Med. 2017;376:1111–20.

CAS  Article  Google Scholar 

Derry S, Bell R F, Straube S, Wiffen P J, Aldington D, Moore R A. Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev. 2019;1: CD007–076.

Yu X, Liu T, Zhao D, Yang K, Zhang X, Zhang M, Zhang S, Huang W, Wu B, Li J. Efficacy and safety of pregabalin in neuropathic pain followed spinal cord injury: a review and meta-analysis of randomized controlled trials. Clin J Pain. 2019;35:272–8.

Article  Google Scholar 

Canos A, Cort L, Fernández Y, Rovira V, Pallarés J, Barberá M, Morales-Suárez-Varela M. Preventive analgesia with pregabalin in neuropathic pain from “failed back surgery syndrome”: assessment of sleep quality and disability. Pain Med. 2016;17:344–52.

CAS  PubMed  Google Scholar 

Ueda H. Lysophosphatidic acid signaling is the definitive mechanism underlying neuropathic pain. Pain. 2017;158:S55–65.

Uranbileg B, Ito N, Kurano M, Saigusa D, Saito R, Uruno A, Kano K, Ikeda H, Yamada Y, Sumitani M, Sekiguchi M, Aoki J, Yatomi Y. Alteration of the lysophosphatidic acid and its precursor lysophosphatidylcholine levels in spinal cord stenosis: a study using a rat cauda equina compression model. Sci Rep. 2019;9:16578.

Article  Google Scholar 

Tsuchida R, Tanabe Y, Nishizawa D, Ikeda K, Abe H, Inoue R, Kurano M, Yatomi Y, Tamura K, Takano T, Shimizu C, Uchida K, Sumitani M. Genetic polymorphisms of lysophosphatidic acid receptor 1 are associated with the onset of taxane-induced peripheral neuropathy. Br J Anaesth. 2021;127:e43–6.

CAS  Article  Google Scholar 

Hayakawa K, Kurano M, Ohya J, Oichi T, Kano K, Nishikawa M, Uranbileg B, Kuwajima K, Sumitani M, Tanaka S, Aoki J, Yatomi Y, Chikuda H. Lysophosphatidic acids and their substrate lysophospholipids in cerebrospinal fluid as objective biomarkers for evaluating the severity of lumbar spinal stenosis. Sci Rep. 2019;9:9144.

Article  Google Scholar 

Uranbileg B, Ito N, Kurano M, Kano K, Uchida K, Sumitani M, Aoki K, Yatomi Y. Inhibition of autotaxin activity ameliorates neuropathic pain derived from lumbar spinal canal stenosis. Sci Rep. 2021;11:3984.

CAS  Article  Google Scholar 

Kuwajima K, Sumitani M, Kurano M, Kano K, Nishikawa M, Uranbileg B, Tsuchida R, Ogata R, Aoki J, Yatomi Y, Yamada Y. Lysophosphatidic acid is associated with neuropathic pain intensity in humans: An exploratory study. PLoS ONE. 2018;13: e0207310.

Article  Google Scholar 

Bandoh K, Aoki J, Taira A, Tsujimoto M, Arai H, Inoue K. Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors. FEBS Lett. 2000; 478: 159–65

Ma L, Nagai J, Chun J, Ueda H. An LPA species (18:1 LPA) plays key roles in the self-amplification of spinal LPA production in the peripheral neuropathic pain model. Mol Pain. 2013;17(9):29.

Google Scholar 

Treede R-D, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, Hansson P, Hughes R, Nurmikko T, Serra J. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70:1630–5.

CAS  Article  Google Scholar 

Sakai E, Kurano M, Morita Y, Aoki J, Yatomi Y. Establishment of a measurement system for sphingolipids in the cerebrospinal fluid based on liquid chromatography-tandem mass spectrometry, and its application in the diagnosis of carcinomatous meningitis. J Appl Lab Med. 2020;5:656–70.

Article  Google Scholar 

Morita Y, Kurano M, Sakai E, Nishikawa M, Sawabe M, Aoki J, Yatomi Y. Evaluation of lysophospholipid measurement in cerebrospinal fluid samples using liquid chromatography-tandem mass spectrometry. Lipids. 2019;54:487–500.

CAS  Article  Google Scholar 

Inoue R, Sumitani M, Ogata T, Chikuda H, Matsubara T, Kato S, Shimojo N, Uchida K, Yamada Y. Direct evidence of central nervous system axonal damage in patients with postoperative delirium: a preliminary study of pNF-H as a promising serum biomarker. Neurosci Lett. 2017;653:39–44.

CAS  Article  Google Scholar 

Natori A, Ogata T, Sumitani M, Kogure T, Yamauchi T, Yamauchi H. Potential role of pNF-H, a biomarker of axonal damage in the central nervous system, as a predictive marker of chemotherapy-induced cognitive impairment. Clin Cancer Res. 2015;21:1348–52.

CAS  Article  Google Scholar 

Sumitani M, Ogata T, Natori A, Hozumi J, Shimojo N, Kida K, Yamauchi H, Yamauchi T. Poor efficacy of the phosphorylated high-molecular-weight neurofilament heavy subunit serum level, a biomarker of axonal damage, as a marker of chemotherapy-induced peripheral neuropathy. Biomed Rep. 2016;4:758–60.

CAS  Article  Google Scholar 

Ohya J, Chikuda H, Kato S, Hayakawa K, Oka H, Takeshita K, Tanaka S, Ogata T. Elevated levels of phosphorylated neurofilament heavy subunit in the cerebrospinal fluid of patients with lumbar spinal stenosis: preliminary findings. Spine J. 2015;15:1587–92.

Article  Google Scholar 

Michalcczyk A, Budkowska M, Dolegowska B, Chlubek D, Safranow K. Lysophosphatidic acid plasma concentrations in healthy subjects: circadian rhythm and associations with demographic, anthropometric and biochemical parameters. Lipids Health Dis. 2017;16:140.

Article  Google Scholar 

Inoue M, Ma L, Aoki J, Chun J, Ueda H. Autotaxin, a synthetic enzyme of lysophosphatidic acid (LPA), mediates the induction of nerve-injured neuropathic pain. Mol Pain. 2008;4:6.

Article  Google Scholar 

Inoue M, Rashid MH, Fujita R, Contos JJA, Chun J, Ueda H. Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling. Nat Med. 2004;10:712–8.

CAS  Article  Google Scholar 

Ueda H. Molecular mechanisms of neuropathic pain-phenotypic switch and initiation mechanisms. Pharmacol Ther. 2006;109:57–77.

CAS  Article  Google Scholar 

Hemmings DG, Brindley DN. Signalling by lysophosphatidate and its health implications. Essays Biochem. 2020;64:547–63.

CAS  Article  Google Scholar 

Yu P, Agbaegbu C, Malide DA, Wu X, Katagiri Y, Hammer JA, Geller HM. Cooperative interactions of LPPR family members in membrane localization and alteration of cellular morphology. J Cell Sci. 2015;128:3210–22.

CAS  PubMed  PubMed Central  Google Scholar 

Strauss U, Bräuer AU. Current views on regulation and function of plasticity-related genes (PRGs/LPPRs) in the brain. Biochim Biophys Acta. 2013;1831:133–8.

CAS  Article  Google Scholar 

Ma L, Nagai J, Chun J, Ueda H. An LPA species (18:1 LPA) plays key roles in the self-amplification of spinal LPA production in the peripheral neuropathic pain model. Mol Pain. 2013;9:29.

CAS  Article  Google Scholar 

Matsuoka H, Tanaka H, Sayanagi J, Iwahashi T, Suzuki K, Nishimoto S, Okada K, Murase T, Yoshikawa H. Neurotropin ® accelerates the differentiation of schwann cells and remyelination in a rat lysophosphatidylcholine-induced demyelination model. Int J Mol Sci. 2018;19:516.

Article  Google Scholar 

Sattikar A, Dowling MR, Rosethorne EM. Endogenous lysophosphatidic acid (LPA1) receptor agonists demonstrate ligand bias between calcium and ERK signaling pathways in human lung fibrosis. Br J Pharmacol. 2017;174:227–37.

CAS  Article  Google Scholar